{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T19:23:13Z","timestamp":1790796193899,"version":"4.1.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T00:00:00Z","timestamp":1747872000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T00:00:00Z","timestamp":1747872000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"NIH\/NEI","award":["EY024951"],"award-info":[{"award-number":["EY024951"]}]},{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","award":["EY029240"],"award-info":[{"award-number":["EY029240"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"name":"NIH","award":["S10OD028576"],"award-info":[{"award-number":["S10OD028576"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-02816-z","type":"journal-article","created":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T06:40:04Z","timestamp":1747896004000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["CTLA-4 expression on tregs is needed for suppression of autoimmune uveitis"],"prefix":"10.1038","volume":"15","author":[{"given":"Minjun","family":"Ahn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Dostal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya","family":"Hegde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darren J.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,22]]},"reference":[{"key":"2816_CR1","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1001\/archopht.1962.00960030506014","volume":"68","author":"RW Darrell","year":"1962","unstructured":"Darrell, R. W., Wagener, H. P. & Kurland, L. T. Epidemiology of uveitis. Incidence and prevalence in a small urban community. Arch. Ophthalmol. 68, 502\u2013514 (1962).","journal-title":"Arch. Ophthalmol."},{"issue":"11","key":"2816_CR2","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1016\/j.ophtha.2012.05.026","volume":"119","author":"DK Hwang","year":"2012","unstructured":"Hwang, D. K., Chou, Y. J., Pu, C. Y. & Chou, P. Epidemiology of uveitis among the Chinese population in Taiwan: a population-based study. Ophthalmology 119 (11), 2371\u20132376 (2012).","journal-title":"Ophthalmology"},{"issue":"6","key":"2816_CR3","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/j.ajo.2008.09.014","volume":"146","author":"EB Suhler","year":"2008","unstructured":"Suhler, E. B., Lloyd, M. J., Choi, D., Rosenbaum, J. T. & Austin, D. F. Incidence and prevalence of uveitis in veterans affairs medical centers of the Pacific Northwest. Am. J. Ophthalmol. 146 (6), 890\u2013896e898 (2008).","journal-title":"Am. J. Ophthalmol."},{"issue":"1","key":"2816_CR4","first-page":"3","volume":"3","author":"RR Caspi","year":"2006","unstructured":"Caspi, R. R. Animal models of autoimmune and immune-mediated uveitis. Drug Discovery Today: Disease Models. 3 (1), 3\u20139 (2006).","journal-title":"Drug Discovery Today: Disease Models"},{"key":"2816_CR5","doi-asserted-by":"publisher","first-page":"907","DOI":"10.3389\/fimmu.2018.00907","volume":"9","author":"RM Gilbert","year":"2018","unstructured":"Gilbert, R. M. et al. Clinical remission of Sight-Threatening Non-Infectious uveitis is characterized by an upregulation of peripheral T-Regulatory cell polarized towards T-bet and TIGIT. Front. Immunol. 9, 907 (2018).","journal-title":"Front. Immunol."},{"key":"2816_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.intimp.2020.106378","volume":"83","author":"DJ Lee","year":"2020","unstructured":"Lee, D. J. The relationship between TIGIT\u2009+\u2009regulatory T cells and autoimmune disease. Int. Immunopharmacol. 83, 1\u201311 (2020).","journal-title":"Int. Immunopharmacol."},{"key":"2816_CR7","doi-asserted-by":"publisher","first-page":"37790","DOI":"10.1038\/srep37790","volume":"6","author":"DJ Lee","year":"2016","unstructured":"Lee, D. J., Preble, J., Lee, S., Foster, C. S. & Taylor, A. W. MC5r and A2Ar deficiencies during experimental autoimmune uveitis identifies distinct T cell polarization programs and a biphasic regulatory response. Sci. Rep. 6, 37790 (2016).","journal-title":"Sci. Rep."},{"key":"2816_CR8","doi-asserted-by":"publisher","first-page":"102441","DOI":"10.1016\/j.jaut.2020.102441","volume":"111","author":"F Muhammad","year":"2020","unstructured":"Muhammad, F. et al. TIGIT(+) A2Ar-Dependent anti-uveitic Treg cells are a novel subset of Tregs associated with resolution of autoimmune uveitis. J. Autoimmun. 111, 102441 (2020).","journal-title":"J. Autoimmun."},{"key":"2816_CR9","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.mucimm.2023.04.005","volume":"16","author":"K Peters","year":"2023","unstructured":"Peters, K. et al. A2Ar-dependent PD-1\u2009+\u2009and TIGIT\u2009+\u2009Treg cells have distinct homing requirements to suppress autoimmune uveitis in mice. Mucosal. Immunol. 16, 422\u2013431 (2023).","journal-title":"Mucosal. Immunol."},{"issue":"4","key":"2816_CR10","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.4049\/jimmunol.1102415","volume":"188","author":"R Zhou","year":"2012","unstructured":"Zhou, R. et al. The living eye disarms uncommitted autoreactive T cells by converting them to Foxp3(+) regulatory cells following local antigen recognition. J. Immunol. 188 (4), 1742\u20131750 (2012).","journal-title":"J. Immunol."},{"issue":"7","key":"2816_CR11","doi-asserted-by":"publisher","first-page":"3011","DOI":"10.4049\/jimmunol.1402650","volume":"194","author":"PB Silver","year":"2015","unstructured":"Silver, P. B. et al. Retina-specific T regulatory cells bring about resolution and maintain remission of autoimmune uveitis. J. Immunol. 194 (7), 3011\u20133019 (2015).","journal-title":"J. Immunol."},{"issue":"5","key":"2816_CR12","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/1074-7613(95)90125-6","volume":"3","author":"EA Tivol","year":"1995","unstructured":"Tivol, E. A. et al. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 3 (5), 541\u2013547 (1995).","journal-title":"Immunity"},{"issue":"5238","key":"2816_CR13","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1126\/science.270.5238.985","volume":"270","author":"P Waterhouse","year":"1995","unstructured":"Waterhouse, P. et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 270 (5238), 985\u2013988 (1995).","journal-title":"Science"},{"issue":"5899","key":"2816_CR14","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1126\/science.1160062","volume":"322","author":"K Wing","year":"2008","unstructured":"Wing, K. et al. CTLA-4 control over Foxp3\u2009+\u2009regulatory T cell function. Science 322 (5899), 271\u2013275 (2008).","journal-title":"Science"},{"issue":"10","key":"2816_CR15","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1084\/jem.20141030","volume":"212","author":"AM Paterson","year":"2015","unstructured":"Paterson, A. M. et al. Deletion of CTLA-4 on regulatory T cells during adulthood leads to resistance to autoimmunity. J. Exp. Med. 212 (10), 1603\u20131621 (2015).","journal-title":"J. Exp. Med."},{"issue":"17","key":"2816_CR16","doi-asserted-by":"publisher","first-page":"E2383","DOI":"10.1073\/pnas.1603892113","volume":"113","author":"K Klocke","year":"2016","unstructured":"Klocke, K., Sakaguchi, S., Holmdahl, R. & Wing, K. Induction of autoimmune disease by deletion of CTLA-4 in mice in adulthood. Proc. Natl. Acad. Sci. U S A. 113 (17), E2383\u20132392 (2016).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"issue":"6","key":"2816_CR17","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1189\/jlb.3A1014-466RR","volume":"97","author":"DJ Lee","year":"2015","unstructured":"Lee, D. J. & Taylor, A. W. Recovery from experimental autoimmune uveitis promotes induction of antiuveitic inducible Tregs. J. Leukoc. Biol. 97 (6), 1101\u20131109 (2015).","journal-title":"J. Leukoc. Biol."},{"issue":"5","key":"2816_CR18","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1189\/jlb.72.5.946","volume":"72","author":"K Namba","year":"2002","unstructured":"Namba, K., Kitaichi, N., Nishida, T. & Taylor, A. W. Induction of regulatory T cells by the Immunomodulating cytokines alpha-melanocyte-stimulating hormone and transforming growth factor-beta2. J. Leukoc. Biol. 72 (5), 946\u2013952 (2002).","journal-title":"J. Leukoc. Biol."},{"key":"2816_CR19","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.exer.2015.08.012","volume":"140","author":"C Iwahashi","year":"2015","unstructured":"Iwahashi, C. et al. CTLA4-Ig suppresses development of experimental autoimmune uveitis in the induction and effector phases: comparison with Blockade of interleukin-6. Exp. Eye Res. 140, 53\u201364 (2015).","journal-title":"Exp. Eye Res."},{"issue":"6","key":"2816_CR20","doi-asserted-by":"publisher","first-page":"3338","DOI":"10.4049\/jimmunol.1004019","volume":"187","author":"HM Oh","year":"2011","unstructured":"Oh, H. M. et al. Autoreactive memory CD4\u2009+\u2009T lymphocytes that mediate chronic uveitis reside in the bone marrow through STAT3-dependent mechanisms. J. Immunol. 187 (6), 3338\u20133346 (2011).","journal-title":"J. Immunol."},{"issue":"2","key":"2816_CR21","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1111\/imm.12503","volume":"146","author":"J Boldison","year":"2015","unstructured":"Boldison, J. et al. A novel pathogenic RBP-3 peptide reveals epitope spreading in persistent experimental autoimmune uveoretinitis. Immunology 146 (2), 301\u2013311 (2015).","journal-title":"Immunology"},{"issue":"9","key":"2816_CR22","doi-asserted-by":"publisher","first-page":"2598","DOI":"10.1002\/1521-4141(200209)32:9<2598::AID-IMMU2598>3.0.CO;2-#","volume":"32","author":"CA Deeg","year":"2002","unstructured":"Deeg, C. A. et al. Uveitis in horses induced by interphotoreceptor retinoid-binding protein is similar to the spontaneous disease. Eur. J. Immunol. 32 (9), 2598\u20132606 (2002).","journal-title":"Eur. J. Immunol."},{"issue":"3","key":"2816_CR23","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/intimm\/dxm148","volume":"20","author":"M Diedrichs-Mohring","year":"2008","unstructured":"Diedrichs-Mohring, M., Hoffmann, C. & Wildner, G. Antigen-dependent monophasic or recurrent autoimmune uveitis in rats. Int. Immunol. 20 (3), 365\u2013374 (2008).","journal-title":"Int. Immunol."},{"issue":"2","key":"2816_CR24","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.ddmec.2006.05.006","volume":"3","author":"RR Caspi","year":"2006","unstructured":"Caspi, R. R. Mechanisms underlying autoimmune uveitis. Drug Discovery Today: Disease Mech. 3 (2), 199\u2013206 (2006).","journal-title":"Drug Discovery Today: Disease Mech."},{"issue":"2","key":"2816_CR25","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1080\/09273948.2019.1577978","volume":"28","author":"P Sun Mm Md","year":"2020","unstructured":"Sun Mm Md, P. et al. Uveitis in patients treated with CTLA-4 and PD-1 checkpoint Blockade Inhibition. Ocul Immunol. Inflamm. 28 (2), 217\u2013227 (2020).","journal-title":"Ocul Immunol. Inflamm."},{"issue":"3","key":"2816_CR26","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1177\/1120672120930688","volume":"31","author":"J Eikenberry","year":"2021","unstructured":"Eikenberry, J. et al. Ocular side effects of target therapy and immunotherapy in patients with cutaneous malignant melanoma. Eur. J. Ophthalmol. 31 (3), 1391\u20131398 (2021).","journal-title":"Eur. J. Ophthalmol."},{"key":"2816_CR27","doi-asserted-by":"publisher","first-page":"1302293","DOI":"10.3389\/fimmu.2023.1302293","volume":"14","author":"HT Kuo","year":"2023","unstructured":"Kuo, H. T. et al. Association between immune checkpoint inhibitor medication and uveitis: a population-based cohort study utilizing TriNetX database. Front. Immunol. 14, 1302293 (2023).","journal-title":"Front. Immunol."},{"issue":"3","key":"2816_CR28","first-page":"1","volume":"14","author":"H Zhang","year":"2024","unstructured":"Zhang, H., Houadj, L., Wu, K. Y. & Tran, S. D. Diagnosing and managing uveitis associated with immune checkpoint inhibitors: A review. Diagnostics (Basel) 14(3), 1\u201348 (2024).","journal-title":"Diagnostics (Basel)"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-02816-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-02816-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-02816-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T19:02:16Z","timestamp":1748286136000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-02816-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,22]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2816"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-02816-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,22]]},"assertion":[{"value":"1 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"\u201cThe authors declare that they have no competing interests.\u201d","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"17745"}}